NCT04665687 Clinical Application of Genetic Sequencing of Early Gastric Cancer and Gastric Adenoma Patients
| NCT ID | NCT04665687 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Samsung Medical Center |
| Condition | Early Gastric Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,730 participants |
| Start Date | 2020-12-17 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,730 participants in total. It began in 2020-12-17 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Because advanced gastric cancer shows poor prognosis, it is important to detect early gastric cancer or precancerous gastric adenoma patients who have a cure rate of 95% or more. Moreover, a large part of early gastric cancer can be completely resected by endoscopic resection, thus ensuring a very high quality of life for patients. However, there are currently no markers that can be used for diagnosis of early gastric cancer or gastric adenoma. In addition, the biggest problem after endoscopic resection of early gastric cancer is metachronous recurrence of the cancer, which requires repeated endoscopic resection or additional surgical gastrectomy. However, there are no discovered markers for prediction of recurrence. Liquid biopsy is a method of obtaining body fluids such as gastric juice or effusion through an endoscopic inlet during gastroscopy or colonoscopy and blood. Based on the advanced analysis method, liquid biopsy reveals more genetic information than tissue biopsy. Therefore, it is highly likely to become an essential factor in future personalized medicine. Therefore, this study was designed to identify whether tumor's molercular profiling based on tissue or blood could be used for prediction of prognosis and diagnosis of early gastric cancer and precancerous gastric adenoma.
Eligibility Criteria
Inclusion Criteria: 1. Those who are over the age of 19 2. Those who were histologically confirmed with early gastric cancer or precancerous gastric adenoma 3. Patients with early gastric cancer or precancerous gastric adenoma falling under the above criteria who have excess tissue stored from previous non-research purpose biopsy/endodoscopic removal for treatment and diagnosis 4. Those whose life expectancy is more than 3 months 5. Those who have voluntarily consented to participate in this clinical trial Exclusion Criteria: 1. Those who will not yield enough samples 2. Those who are considered inappropriate for this study in the discretion of the researchers
Contact & Investigator
Hyuk Lee, MD, PhD
PRINCIPAL INVESTIGATOR
Samsung Medical Center
Frequently Asked Questions
Who can join the NCT04665687 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, up to 100 Years, studying Early Gastric Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04665687 currently recruiting?
Yes, NCT04665687 is actively recruiting participants. Contact the research team at hyejung1.cho@sbri.co.kr for enrollment information.
Where is the NCT04665687 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT04665687 clinical trial?
NCT04665687 is sponsored by Samsung Medical Center. The principal investigator is Hyuk Lee, MD, PhD at Samsung Medical Center. The trial plans to enroll 1,730 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.